Academic perspectives on the United States food and drug administration's guidance for industry on diabetes mellitus

Contemporary Clinical Trials

Volumn 31, Issue 5, 2010, Pages 411-413

  Hennekens, Charles H ^a   Hebert, Patricia R ^a   Schneider, Wendy R ^a   O'Brien, Peter ^b   DeMets, David ^c   Borer, Jeffrey S ^d  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Food and Drug Administration

Indexed keywords

INSULIN; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ACADEMIC ADVISEMENT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; HYPOTHESIS; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK BENEFIT ANALYSIS; UNITED STATES;

DIABETES MELLITUS; DRUG DESIGN; DRUG INDUSTRY; DRUG TOXICITY; GOVERNMENT REGULATION; GUIDELINES AS TOPIC; HUMANS; HYPOGLYCEMIC AGENTS; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77957751400     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2010.06.001     Document Type: Article

References (12)

1. Guidance for Industry: Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. US DHHS, FDA, CDER, December 2008.
2. Hennekens C.H., Buring J.E., Hebert P. Implications of overviews for randomized trials. Stat Med 1987, 6:397-402.
3. Hennekens C.H., DeMets D. The need for large scale randomized evidence without undue reliance on small trials, their meta-analyses or subgroup analyses. JAMA 2009, 302:2361-2362.
4. L. Friedman, C. Furberg, D. Demets. Fundamentals of Clinical Trials. John Wright-PSG Inc., Littleton, MA, 1981; 3rd edition 1998 Springer-Verlag, New York, NY.
5. Hennekens C.H., Buring J.E. Epidemiology in Medicine 1987, Little, Brown and Company, Boston.
6. Nissen S., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
7. Hennekens C.H., DeMets D., Bairey-Merz C.N., Borzak S., Borer J. Doing more good than harm: the need for a cease fire. AJM 2009, 122:315-316.
8. Home P.D., Pocock S.J., Beck-Nielsen H., et al. For the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007, 357:28-38.
9. Nathan D.M. Rosiglitazone and cardiotoxicity-weighing the evidence. N Engl J Med 2007, 357:64-66.
10. Psaty B.M., Furberg C.D. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 2007, 357:67-69.
11. Home P.D., Pocock S.J., Beck-Nielsen H., et al. For the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
12. LeLorier J., Gregoire G., Benhaddad A., Lapierre J., Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997, 337:536-542.